Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

In this study, 2% of healthcare workers vaccinated with Covaxin or Covishield reported new skin reactions, with a slightly higher incidence following Covaxin; significant differences were observed among paramedical staff.

This report describes the first suspected case of dermatologic adverse effects from subcutaneous furosemide in cats, noting ulcerative skin lesions that resolved after switching the formulation.

This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This study reported significant differences in adverse drug reactions among five chemotherapeutic regimens for oropharyngeal cancer, highlighting nausea/vomiting, alopecia, mucositis, myelosuppression, constitutional symptoms, and dermatological toxicities across different treatments.

In this study, chemotherapy-induced adverse drug reactions were common in cancer patients, highlighting the need for better pharmacovigilance and personalized treatment strategies to reduce their occurrence and severity.

This study used data mining of the FDA Adverse Event Reporting System to analyze drug-induced pruritus, revealing differences in gender, age, and weight among cases, and identified ophthalmic drugs and systemic antibacterials as common triggers, contributing to potential prevention and treatment strategies for pruritus.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This review explores dermatological manifestations and cutaneous drug reactions associated with COVID-19, providing insights for clinicians on recognizing these signs and understanding their potential mechanisms, but it reports no new clinical results.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.

This study reported that chemotherapy-induced skin reactions in cancer patients are mostly mild to moderate and manageable with supportive care, suggesting that early dermatologic intervention can improve patient outcomes without interrupting chemotherapy.

This review discusses various adverse skin reactions linked to cardiovascular medications and reports no new clinical results, highlighting the need for vigilance when prescribing these drugs.

This review discusses the dermatological and systemic adverse effects of hair dye use, particularly focusing on the common allergen para-phenylenediamine, and reports no new clinical data.

This study conducted at Madras Veterinary College found that tick infestation was the most frequent diagnosis among hospitalized dogs with dermatological issues, with ectoparasiticides prescribed in 73% of cases.

This review focuses on the immunologic-based skin conditions that can result from β-blocker use, emphasizing potential adverse dermatologic effects rather than their therapeutic benefits.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This case study observed hair shedding in an 8 1/2-year-old girl treated with carbamazepine, which ceased after stopping the medication.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This study observed a variety of skin conditions related to COVID-19 and its vaccines in a Brazilian setting, classifying them into five categories, including peri-infectious reactions and vaccine-related adverse effects, to aid physicians managing similar cases.

This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.

This review explores how psychotropic medications can cause a range of skin reactions, from mild to life-threatening, and emphasizes the importance of monitoring for these adverse effects early in treatment.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

This narrative review reports that IL-17 and IL-23 inhibitors, while effective for psoriasis and other inflammatory diseases, can cause a variety of skin reactions that resemble primary dermatoses, highlighting the need for careful diagnosis and varied management strategies.

This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.

This review discusses adverse cutaneous drug reactions associated with antidepressants and provides guidance on managing these reactions, but it reports no new clinical findings; the authors recommend cautious use and alternative treatment if reactions occur.

This article discusses the emerging field of supportive oncodermatology, which collaborates between oncology and dermatology to address skin-related side effects of cancer treatments, and reports no new clinical results.

This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.

In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.